203 related articles for article (PubMed ID: 22239503)
21. [Viral factors influencing histological changes of HBeAg-negative chronic hepatitis B patients with persistently normal serum ALT levels].
Yang YH; Xie Q; Wang H; Zhou HJ; Gui HL; Cai W; Guo SM; Yu H; Guo Q
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):434-9. PubMed ID: 19567022
[TBL] [Abstract][Full Text] [Related]
22. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
[TBL] [Abstract][Full Text] [Related]
23. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
[TBL] [Abstract][Full Text] [Related]
25. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection.
Papatheodoridis GV; Chrysanthos N; Hadziyannis E; Cholongitas E; Manesis EK
J Viral Hepat; 2008 Jun; 15(6):434-41. PubMed ID: 18194171
[TBL] [Abstract][Full Text] [Related]
27. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
28. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
29. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters.
Tseng TC; Liu CJ; Chen CL; Wang CC; Su TH; Kuo SF; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2012 Jan; 205(1):54-63. PubMed ID: 22095766
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels.
Lin CL; Liao LY; Liu CJ; Yu MW; Chen PJ; Lai MY; Chen DS; Kao JH
Hepatology; 2007 May; 45(5):1193-8. PubMed ID: 17464993
[TBL] [Abstract][Full Text] [Related]
32. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.
Manesis EK; Papatheodoridis GV; Sevastianos V; Cholongitas E; Papaioannou C; Hadziyannis SJ
Am J Gastroenterol; 2003 Oct; 98(10):2261-7. PubMed ID: 14572577
[TBL] [Abstract][Full Text] [Related]
33. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).
Zacharakis GH; Koskinas J; Kotsiou S; Papoutselis M; Tzara F; Vafeiadis N; Archimandritis AJ; Papoutselis K
J Med Virol; 2005 Oct; 77(2):173-9. PubMed ID: 16121378
[TBL] [Abstract][Full Text] [Related]
34. [Relationship among pathological changes in Liver tissues and level of serum HBV DNA, HBeAg and ALT of 194 patients with chronic hepatitis B].
Zhao DY; Qin YQ; Tang XM; Liu GZ; Zheng W; Nong HR; Song JJ; Xie QY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):35-7. PubMed ID: 17429530
[TBL] [Abstract][Full Text] [Related]
35. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B.
Xie Q; Hu X; Zhang Y; Jiang X; Li X; Li J
J Med Virol; 2014 Nov; 86(11):1828-37. PubMed ID: 25145769
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.
Feld JJ; Ayers M; El-Ashry D; Mazzulli T; Tellier R; Heathcote EJ
Hepatology; 2007 Oct; 46(4):1057-70. PubMed ID: 17654702
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of liver biopsy in Egyptian HBeAg-negative chronic hepatitis B patients at initial presentation: implications for therapy.
El-Zayadi AR; Badran HM; Saied A; Shawky S; Attia Mel-D; Zalata K
Am J Gastroenterol; 2009 Apr; 104(4):906-11. PubMed ID: 19293791
[TBL] [Abstract][Full Text] [Related]
38. Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia.
Lesmana CR; Gani RA; Hasan I; Simadibrata M; Sulaiman AS; Pakasi LS; Budihusodo U; Krisnuhoni E; Lesmana LA
J Dig Dis; 2011 Dec; 12(6):476-80. PubMed ID: 22118698
[TBL] [Abstract][Full Text] [Related]
39. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
40. HBV DNA level and antigen concentration in evaluating liver damage of patients with chronic hepatitis B.
Xie Y; Zhao H; Dai WS; Xu DZ
Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):418-22. PubMed ID: 14599951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
